PERSPECTIVES: Alzheimer's Disease
Louie talks with Donald E. Moss, PhD, neuroscientist, researcher, and author of "Alzheimer's: My Journey to a Next Generation Treatment." Moss talks about the development of the drug MSF which has been shown in animal & human trials to selectively boost acetylcholine in the brains of Alzheimer's patients without the side effects of medicines on the market today which also boost acetylcholine levels. It would cost hundreds of millions of dollars to get FDA approval on MSF, so it has essentially fallen through the cracks. Moss and his colleagues are currently looking for private sources of funding to continue their research and eventually offer it to Alzheimer's patients at the staggeringly low cost of $1-$2 dollars a day. Learn more about MSF and about plans to make MSF available to the public at http://brain-tools.com. Aired Feb. 9, 2013.